A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 28, 2028

Study Completion Date

July 29, 2030

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Pirtobrutinib

Patients will receive pirtobrutinib orally with dosing schedule as prescribed

DRUG

Acalabrutinib

Patients will receive acalabrutinib orally with dosing schedule as prescribed.